DOPATREE
Preview
Open in TheBrain
DOPATREE
ORGANIZATIONS
COMPANIES-ALL (COMPANY, CLIENTS, SPONSORS, SMALL, MID-SIZE, LARGE PHARMA, BIG PHARMA, BIOPHARMA, EMERGING COMPANIES, STARTUPS, START-UPS, SPIN-OFFS, SUBSIDIARIES, SUBSIDIARY, BIOTECHNOLOGY, EMERGING)
COMPANIES / LISTINGS-N
NOVARTIS
NOVARTIS / PRODUCTS / APPROVED
PLUVICTO™ (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN)
PLUVICTO / WARNINGS AND PRECAUTIONS
NEPHROTOXICITY (RENAL TOXICITY, DRUG-INDUCED)
NEPHROTOXICITY / MITIGATIONS
Parents
NEPHROTOXICITY (RENAL TOXICITY, DRUG-INDUCED)
Children
ADVISE PATIENT TO URINATE FREQUENTLY DURING AND AFTER DRUG ADMINISTRATION
AVOID USE IN PATIENTS EGRF <30 ML/MIN
DISCONTINUE TREATMENT IF SEVERE RENAL IMPAIRMENT DEVELOPS
MONITOR CALCULATED CREATININE CLEARANCE
MONITOR SERUM CREATININE AT BASELINE AND DURING THERAPY